Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 465.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,781 shares of the company's stock after buying an additional 35,214 shares during the period. Nisa Investment Advisors LLC owned about 0.05% of Verve Therapeutics worth $241,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Green Alpha Advisors LLC increased its position in shares of Verve Therapeutics by 15.0% in the 4th quarter. Green Alpha Advisors LLC now owns 29,438 shares of the company's stock worth $166,000 after purchasing an additional 3,840 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Verve Therapeutics by 20.9% in the 3rd quarter. Franklin Resources Inc. now owns 34,155 shares of the company's stock worth $172,000 after purchasing an additional 5,914 shares during the last quarter. Barclays PLC increased its position in shares of Verve Therapeutics by 139.8% in the 3rd quarter. Barclays PLC now owns 222,919 shares of the company's stock worth $1,079,000 after purchasing an additional 129,944 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Verve Therapeutics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company's stock worth $7,749,000 after purchasing an additional 40,915 shares during the last quarter. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Stock Performance

Shares of NASDAQ VERV traded down $0.29 during midday trading on Thursday, hitting $7.41. The company's stock had a trading volume of 1,140,236 shares, compared to its average volume of 1,741,597. Verve Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $19.34. The firm's fifty day moving average price is $6.13 and its 200-day moving average price is $5.84. The firm has a market cap of $627.33 million, a P/E ratio of -3.01 and a beta of 1.68.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.11. The firm had revenue of $6.87 million during the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Verve Therapeutics's revenue was up 120.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.72) EPS. As a group, research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VERV has been the subject of several research analyst reports. Royal Bank of Canada dropped their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Finally, HC Wainwright decreased their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.